RESUMO
Rheumatoid arthritis (RA) is a chronic inflammatory disease caused by a faulty autoimmune response. Recently, it was reported that some human carbonic anhydrases (CAs) isoforms are overexpressed in inflamed synovium of RA patients. New CA inhibitors (CAIs) incorporating CA-binding moiety and the cyclooxygenase inhibitor tail (nonsteroidal anti-inflammatory drug [NSAID] type) were studied. The aim of this work is the evaluation of the chemical stability of NSAID - CAI hybrids towards spontaneous or enzymatic hydrolysis by LC-MS/MS. The analytes are isomer pairs of 6- or 7-hydroxycoumarin, their different fragment ions abundances allowed the development of a mathematical tool (LEDA) to distinguish them. LEDA reliability at ng mL-1 level was checked (>90%), being proved the effectiveness in the correct assignment of the isomer present in the sample. The hybrids resulted stable in all tested matrices allowing us to conclude that these compounds reach the target tissues unmodified, opening perspectives for their development in the treatment of inflammation.
Assuntos
Anti-Inflamatórios não Esteroides/sangue , Inibidores da Anidrase Carbônica/sangue , Anti-Inflamatórios não Esteroides/química , Anti-Inflamatórios não Esteroides/farmacologia , Inibidores da Anidrase Carbônica/química , Inibidores da Anidrase Carbônica/farmacologia , Anidrases Carbônicas/química , Anidrases Carbônicas/metabolismo , Cromatografia Líquida , Humanos , Hidrólise , Estereoisomerismo , Relação Estrutura-Atividade , Espectrometria de Massas em TandemRESUMO
PURPOSE: To characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of acetazolamide (ACTZ) in peritoneal dialysis patients, ACTZ 500 mg was administered intravenously to 7 healthy subjects (HV) and 8 peritoneal dialysis patients (CAPD). METHODS: Population PK/PD modeling was performed with ACTZ serum (total and unbound), urine and dialysate concentrations, intra-ocular pressure (IOP) and covariates. A multi-compartment PK model (accounting for non-linear protein binding) and an inhibitory Emax (maximal change in IOP) PD model were selected. RESULTS: As expected, renal clearance (which almost equals total body clearance) was severely decreased in CAPD (1.2 vs 80.3 L/h) and the elimination half-life of total ACTZ was prolonged (20.6 vs 3.4 hours). The protein binding was significantly altered with a mean free fraction 4.2% in HV and 8.6% in CAPD. Moreover protein binding of ACTZ was concentration dependent in both HV and CAPD. Despite a higher free fraction of ACTZ, the Emax was lower in CAPD: 4.4±1.4 vs 7.4±2.8 mmHg. CONCLUSION: Both PK and PD are significantly altered in dialysis patients.
Assuntos
Acetazolamida/farmacologia , Inibidores da Anidrase Carbônica/farmacologia , Modelos Biológicos , Diálise Peritoneal , Acetazolamida/sangue , Acetazolamida/urina , Adulto , Proteínas Sanguíneas/metabolismo , Inibidores da Anidrase Carbônica/sangue , Inibidores da Anidrase Carbônica/urina , Feminino , Humanos , Testes de Função Renal , Masculino , Pessoa de Meia-Idade , Ligação Proteica , Adulto JovemRESUMO
Single-and multiple-dose pharmacokinetics and safety were investigated in this phase 1 study of dichlorphenamide, a carbonic anhydrase inhibitor approved in the United States for treatment of primary periodic paralysis. Dichlorphenamide was administered to 6 cohorts (n = 6 each) of healthy adults. Cohorts A through E received single doses of 25-400 mg followed by 50-800 mg/day in divided doses for 10 total doses. Cohort F (safety analysis only) received up to 28 titrated doses from 100-800 mg/day. Plasma for pharmacokinetics sampling was obtained predose and up to 48 hours postdose. Twenty-five of 36 enrolled subjects completed. Median time to maximum plasma concentration ranged from 1.5-3 hours, and mean half-life from 32-68 hours. Mean area under the concentration-time curve from time 0 to tau (length of the dosing interval estimated using the trapezoidal method) and maximum observed plasma concentration increased dose-proportionally after multiple doses. The incidence and severity of adverse events (AEs) were dose-related, with at least one mild AE reported among 17%, 17%, and 67% of patients in cohorts A, B, and C, respectively; and at least one mild-to-moderate AE among 100% of subjects in cohorts D, E, and F. One serious AE of rash was reported in cohort F. Eleven subjects discontinued; 10 due to AEs at 400 or 800 mg/day (cohorts E and F), including 100% of cohort F. Hypokalemia contributed to 5 of 6 discontinuations in cohort F (all 800 mg/day).
Assuntos
Inibidores da Anidrase Carbônica/administração & dosagem , Diclorofenamida/administração & dosagem , Adulto , Inibidores da Anidrase Carbônica/efeitos adversos , Inibidores da Anidrase Carbônica/sangue , Inibidores da Anidrase Carbônica/farmacocinética , Diclorofenamida/efeitos adversos , Diclorofenamida/sangue , Diclorofenamida/farmacocinética , Esquema de Medicação , Feminino , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Método Simples-CegoRESUMO
The knowledge on real-time neurophysiological effects of acetazolamide is still far behind the wide clinical use of this drug. Acetazolamide - a carbonic anhydrase inhibitor - has been shown to affect the neuromuscular transmission, implying a pH-mediated influence on the central synaptic transmission. To start filling such a gap, we chose a central substrate: hippocampal-prefrontal cortical projections; and a synaptic phenomenon: paired-pulse facilitation (a form of synaptic plasticity) to probe this drug's effects on interareal brain communication in chronically implanted rats. We observed that systemic acetazolamide potentiates the hippocampal-prefrontal paired-pulse facilitation. In addition to this field electrophysiology data, we found that acetazolamide exerts a net inhibitory effect on prefrontal cortical single-unit firing. We propose that systemic acetazolamide reduces the basal neuronal activity of the prefrontal cortex, whereas increasing the afferent drive it receives from the hippocampus. In addition to being relevant to the clinical and side effects of acetazolamide, these results suggest that exogenous pH regulation can have diverse impacts on afferent signaling across the neocortex.
Assuntos
Acetazolamida/farmacologia , Inibidores da Anidrase Carbônica/farmacologia , Neurônios Aferentes/efeitos dos fármacos , Córtex Pré-Frontal/efeitos dos fármacos , Acetazolamida/efeitos adversos , Acetazolamida/sangue , Animais , Inibidores da Anidrase Carbônica/efeitos adversos , Inibidores da Anidrase Carbônica/sangue , Anidrases Carbônicas/fisiologia , Estimulação Elétrica , Hipocampo/efeitos dos fármacos , Hipocampo/enzimologia , Hipocampo/fisiologia , Masculino , Plasticidade Neuronal/efeitos dos fármacos , Córtex Pré-Frontal/fisiologia , Ratos , Ratos Wistar , Transmissão Sináptica/efeitos dos fármacos , Transmissão Sináptica/fisiologiaRESUMO
This article describes reverse phase high-performance liquid chromatography (RPHPLC) methods for determination of diuretics in different human body fluids (whole blood, plasma, serum or urine). Sample preparation procedures, including solid-phase extraction, liquid-liquid extraction, dilution, precipitation as well as automated RPHPLC procedures, are discussed in order to present the advantages and disadvantages of each type of sample preparation. Also, values of analytical recovery of each procedure used for sample preparation are summarized. The most important RPHPLC parameters (detection mode, stationary phase, mobile phase, sensitivity, etc.) are also summarized and discussed.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Diuréticos/análise , Inibidores da Anidrase Carbônica/análise , Inibidores da Anidrase Carbônica/sangue , Inibidores da Anidrase Carbônica/urina , Diuréticos/sangue , Diuréticos/urina , Humanos , Reprodutibilidade dos Testes , Bloqueadores dos Canais de Sódio/análise , Bloqueadores dos Canais de Sódio/sangue , Bloqueadores dos Canais de Sódio/urina , Inibidores de Simportadores de Cloreto de Sódio e Potássio/análise , Inibidores de Simportadores de Cloreto de Sódio e Potássio/sangue , Inibidores de Simportadores de Cloreto de Sódio e Potássio/urina , Espectrometria de Fluorescência , Espectrofotometria UltravioletaRESUMO
In the current study, a rapid and sensitive LC-QTOF-MS/MS method for the determination of brinzolamide in dried blood spots (DBS) was developed and validated. This novel sample collection, storage and transfer technique was suitable for analyzing a drug with high distribution into red blood cells and negligible plasma levels. The method included an isocratic mobile phase consisting of methanol and 10mM ammonium formate (90:10, v/v) and detection in positive electrospray mode (ESI+). The flow rate was adjusted to 0.350mL/min yielding retention times of 1.7min for both brinzolamide and internal standard (IS) rabeprazole on a Cyano analytical column, respectively. The validation of the proposed method over the concentration range 0.500-20.0µg/mL was performed in compliance with EMEA and FDA guidelines, assessing all major performance characteristics. Inter- and intra- assay precisions were less than 14%, while inter- and intra- assay accuracies varied from 92.2 to 111%. No matrix effect was observed and the mean brinzolamide extraction recovery was 93.5%. The method was successfully applied to real DBS samples from patients in steady state condition, receiving brinzolamide ophthalmic suspension 1% (w/v) for several months. Initial concentrations were corrected due to hematocrit effect, using image processing algorithm written in Matlab.
Assuntos
Inibidores da Anidrase Carbônica/sangue , Cromatografia Líquida de Alta Pressão/métodos , Teste em Amostras de Sangue Seco/métodos , Sulfonamidas/sangue , Espectrometria de Massas em Tandem/métodos , Tiazinas/sangue , Administração Oftálmica , Idoso , Inibidores da Anidrase Carbônica/administração & dosagem , Inibidores da Anidrase Carbônica/uso terapêutico , Cromatografia Líquida de Alta Pressão/instrumentação , Teste em Amostras de Sangue Seco/instrumentação , Eritrócitos/química , Humanos , Masculino , Soluções Oftálmicas , Padrões de Referência , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Sulfonamidas/administração & dosagem , Sulfonamidas/uso terapêutico , Espectrometria de Massas em Tandem/instrumentação , Tiazinas/administração & dosagem , Tiazinas/uso terapêuticoRESUMO
Potential systemic effects of the racemic carbonic anhydrase inhibitor MK-927 and its S-enantiomer, sezolamide hydrochloride, after topical ocular administration were investigated in a double-masked, randomized, placebo-controlled study in 16 healthy volunteers. A controlled diet was started 4 days before initiation of treatment and continued throughout the study. For 14 days six volunteers received bilaterally one drop of 2% MK-927 (1.2 mg) q.i.d., six received one drop of 1.8% sezolamide (1.1 mg) q.i.d., and four received the common vehicle q.i.d. Blood and urine electrolytes and acid-base profiles were measured before and on days 1, 7, and 14 of treatment, and 24-hour urine samples were collected daily. All values were compared with those on the pretreatment day. Taking the circadian variations of the parameters into account, no significant treatment effect was observed in either the daily profiles or the 14-day cumulative sodium, potassium, and citrate excretions. Because the usual variability of the measured biologic parameters has been reduced markedly by the stringent requirements of this study, it can be concluded that the induction of clinically significant metabolic changes by topically administered MK-927 or sezolamide is unlikely.
Assuntos
Inibidores da Anidrase Carbônica/farmacologia , Sulfonamidas/farmacologia , Tiofenos/farmacologia , Administração Tópica , Adulto , Pressão Sanguínea/efeitos dos fármacos , Inibidores da Anidrase Carbônica/sangue , Inibidores da Anidrase Carbônica/urina , Eletrocardiografia/efeitos dos fármacos , Eletrólitos/urina , Olho , Frequência Cardíaca/efeitos dos fármacos , Humanos , Concentração de Íons de Hidrogênio , Rim/metabolismo , Masculino , Soluções Oftálmicas , Sulfonamidas/sangue , Sulfonamidas/urina , Tiofenos/sangue , Tiofenos/urinaRESUMO
Multiple serum chemical values were examined in 92 patients with chronic glaucoma who were treated with the carbonic anhydrase inhibitors (CAIs) acetazolamide or methazolamide, seeking relationships between serum composition and symptomatic side effects. Of the 92 patients, 44 complained of a symptom-complex of malaise, fatigue, weight loss, depression, anorexia, and loss of libido, which we have found most commonly to threaten continuation of therapy. Patients who had this symptom complex were significantly more acidotic than those without it. Ten of 24 patients who had chemical evidence of excessive acidosis reported a dramatic alleviation of symptoms when sodium bicarbonate was administered, although their serum CO2-combining power changed little. There was no correlation of the symptom complex with serum potassium concentration, except in a few patients who were simultaneously receiving chlorothiazide diuretics for systemic hypertension and who became frankly hypokalemic.
Assuntos
Inibidores da Anidrase Carbônica/efeitos adversos , Acetazolamida/efeitos adversos , Bicarbonatos/uso terapêutico , Dióxido de Carbono/sangue , Inibidores da Anidrase Carbônica/sangue , Inibidores da Anidrase Carbônica/uso terapêutico , Doença Crônica , Glaucoma/sangue , Glaucoma/tratamento farmacológico , Humanos , Metazolamida/efeitos adversos , Potássio/sangueRESUMO
Carbonic anhydrase (CA) activity was measured by the Bowes-Davis technique in diluted hemolysates of dog erythrocytes, rabbit erythrocytes, and dog lung tissue homogenates. Plasma (from the same animal) inhibited the CA activity in each case. For 1:16,700 dilution of dog erythrocytes, the CA catalyzed the CO2 hydration reaction by 5.3 +/- 0.4-fold above the uncatalyzed rate, and half that activity was inhibited by plasma concentrations of 0.44 +/- 0.05%. Similar rabbit CA concentrations were inhibited by plasma concentrations of 1.02 +/- 0.24%. CA from dog lung tissue homogenate is only partially inhibited by plasma even at high plasma concentrations, suggesting different isozymes, at least one of which is not inhibited by plasma. The results suggest that extrapolating from artificially perfused lungs or histological observations to in vivo conditions may not be valid, and the possibility of inhibition by plasma in at least some species should be considered.
Assuntos
Inibidores da Anidrase Carbônica/sangue , Cães/sangue , Coelhos/sangue , Animais , Inibidores da Anidrase Carbônica/farmacologia , Eritrócitos/enzimologia , Pulmão/enzimologiaRESUMO
A method for the simultaneous determination of a topical carbonic anhydrase inhibitor, L-693,612, and two of its potential metabolites in human whole blood is described. The analytes are isolated from the matrix via liquid-liquid extraction with a mixture of toluene, ethyl acetate and isopropanol (49:50:1, v/v/v). The analytes are then back extracted into dilute phosphoric acid prior to injection into the HPLC system. A cyano column (Zorbax SB-CN, 150 x 4.6 mm) with a mobile phase of phosphoric acid(0.085%)-acetonitrile (73.5:26.5) containing 10 mM sodium decane sulfonate and adjusted to pH 3 is used for the analysis. Detection is based on UV absorbance at 252 nm. The assay was found to be linear in the concentration range of 5-500 ng/ml for each analyte when 1-ml aliquots of whole blood were extracted.
Assuntos
Inibidores da Anidrase Carbônica/sangue , Cromatografia Líquida de Alta Pressão/métodos , Sulfonamidas/sangue , Tiofenos/sangue , Humanos , Íons , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Espectrofotometria UltravioletaRESUMO
OBJECTIVES: In this paper we investigated in humans and in animals the in vitro and in vivo effect of omeprazole upon purified and erythrocyte carbonic anhydrase (CA) I and II isozymes, as well as on gastric mucosa CA IV. METHOD: In vitro, we observed the effect of omeprazole at concentrations between 10(-8)-10(-4) M on purified CA I and CA II, and also on isolated gastric mucosa CA IV, renal and pulmonary CA IV activity, using the dose-response relationship. In vivo, we studied the effect of omeprazole (Losec) on gastric CA I, II and IV, as well as on erythrocyte CA I and CA II, in humans and in animals. RESULTS: In vitro omeprazole inhibits pH-dependent purified CA I and CA II and gastric mucosa CA IV according to dose-response relationship. In vivo, the i.v. administration of omeprazole in rabbits and in humans shows a decrease of erythrocyte CA I and CA II activity as well as of gastric mucosa CA I, II and IV. CONCLUSIONS: Omeprazole in its active form (sulfenamide) selectively inhibits gastric mucosa CA IV and does not modify the activity of the same isozyme from the kidney and lung proving that the enzyme has an organ specificity. Our results lead to the conclusion that omeprazole possesses a dual mechanism of action: both H+K+ATPase and CA inhibition--enzymes that could be in a functional coupling. This dual mechanism of action might explain the higher effectiveness of treatment using substituted benzimidazole inhibitors compared to other therapies.
Assuntos
Inibidores da Anidrase Carbônica/farmacologia , Anidrases Carbônicas/efeitos dos fármacos , Eritrócitos/efeitos dos fármacos , Mucosa Gástrica/efeitos dos fármacos , Omeprazol/farmacologia , Adulto , Animais , Inibidores da Anidrase Carbônica/sangue , Anidrases Carbônicas/metabolismo , Linhagem Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Eritrócitos/enzimologia , Mucosa Gástrica/enzimologia , Humanos , Concentração de Íons de Hidrogênio , Isoenzimas/efeitos dos fármacos , Isoenzimas/metabolismo , Masculino , Omeprazol/sangue , Coelhos , SuínosRESUMO
A sensitive and specific method for the determination of dorzolamide (I) and its de-ethylated metabolite (II) in human plasma has been developed utilizing high pressure liquid chromatography (HPLC) with tandem mass spectrometric (MS/MS) detection. The analytes and internal standard (III) were isolated from the deproteinized pH 8.0 buffered plasma, using a liquid-liquid extraction with a mixture of ethyl acetate, toluene, and isopropanol. The analytes were then back extracted into 0.085% phosphoric acid (200 microliters) and after washing the acidic extract with hexane, the organic layer was discarded and a fraction (50 microliters) of the acid extract was injected into the LC/MS/MS system. The MS/MS detection was performed on a PE Sciex API III tandem mass spectrometer using a heated nebulizer interface. Multiple reaction monitoring of the parent-->product ion combinations of m/z 325-->199, 297-->199, and 397-->306 were used to quantify I, II, and III, respectively. The assay was validated in the concentration ranges of 0.5-100 and 2.5-100 ng ml-1 of plasma for I and II, respectively. The precision of the assays, expressed as coefficients of variation (C.V.%), were less than 10% over the entire concentration range, with adequate assay specificity and accuracy. The LC/MS/MS method provided a 10-fold increase in the sensitivity of I over the previously reported HPLC/UV method [1].
Assuntos
Anti-Hipertensivos/sangue , Inibidores da Anidrase Carbônica/sangue , Sulfonamidas/sangue , Tiofenos/sangue , Anti-Hipertensivos/metabolismo , Inibidores da Anidrase Carbônica/metabolismo , Cromatografia Líquida de Alta Pressão , Cromatografia Líquida , Humanos , Espectrometria de Massas , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Espectrofotometria Ultravioleta , Sulfonamidas/metabolismo , Tiofenos/metabolismoRESUMO
A simple and sensitive high-performance liquid chromatographic method for the analysis of acetazolamide (AZ) in rat blood (plasma/serum, whole blood and serum ultrafiltrate), brain tissue and cerebrospinal fluid (CSF) was described. Quantitative extraction of AZ with ethyl acetate from both buffered plasma and brain tissue homogenate (pH 8.0) was achieved. Each extract was evaporated to dryness and the residue was chromatographed on a reversed-phase column. CSF was directly analysed without extraction step. The limits of detection were 0.05 microgram ml-1 for plasma, 0.02 microgram g-1 for brain tissue and 0.004 microgram ml-1 for CSF. Calibration curves were linear over the working ranges of 0.1-100 micrograms ml-1 for plasma, 0.05-50 micrograms g-1 for brain tissue and 0.025-50 micrograms ml-1 for CSF. The reproducibility of AZ assay in the rat biologic media indicated very low relative standard deviations (RSDs). The recoveries of AZ added to plasma and brain tissue were more than 96% with an RSD of less than 5%. The present method was applied to studies of plasma concentration profiles of the drug after administration and its distribution into central nervous system.
Assuntos
Acetazolamida/análise , Química Encefálica , Inibidores da Anidrase Carbônica/análise , Cromatografia Líquida de Alta Pressão/métodos , Acetazolamida/sangue , Acetazolamida/líquido cefalorraquidiano , Acetazolamida/farmacocinética , Animais , Inibidores da Anidrase Carbônica/sangue , Inibidores da Anidrase Carbônica/líquido cefalorraquidiano , Inibidores da Anidrase Carbônica/farmacocinética , Injeções Intravenosas , Masculino , Ratos , Ratos Wistar , Distribuição TecidualRESUMO
Dorzolamide is a powerful inhibitor of carbonic anhydrase (CA) II that penetrates the sclera and cornea to reach the ciliary process and lowers formation of HCO3 and aqueous humor. The usual dose applied to the eye in treatment of glaucoma is 1 drop (30 microL of 2% solution) every 8 hr to each eye, or a total daily dose of 4 mg. On this regime, the red cells accumulated drug over a period of 8 days, reaching a value of 20-25 microM, which corresponds to the concentration of CA II in human red cells. This drug concentration persisted throughout the 18 months of application. The plasma concentration was 0.034 microM, or 1/700 that of the red cells. This plasma concentration corresponds to that calculated from the dilution of administered drug into body water. The data are well fitted into the equilibrium expression for KI of dorzolamide against CA II at 37 degrees C, as 8 x 10(-9) M. The red cells also contain a small amount (5 microM) of the N-des-ethyl metabolite, probably reflecting its modest binding to CA I. In the initial 8-day drug period, virtually none appeared in the urine since CA II sites were being filled. At steady state, renal excretion was 1.3 mg/day and the renal clearance 90 ml/min. These excretion numbers include the small (20%) amount of the des-ethyl metabolite of dorzolamide. The relation of these data to lowering of intraocular pressure is clear. By the systemic route, an inhibitor such as acetazolamide is effective when free drug concentration in plasma is 2.5 microM. In the case of topical drugs, as shown here, the plasma concentration is some 100 x lower, but the concentration in ciliary process is 2-10 microM, comparable to that following systemic drugs (1). In conclusion, the concentration in plasma (reflecting free drug) of dorzolamide is about 1/200 of that needed for systemic effects as seen following acetazolamide or methazolamide. Thus, there is a clear pharmacological basis for the lack of any physiological effects of ocular dorzolamide, except on the eye itself.
Assuntos
Inibidores da Anidrase Carbônica/farmacocinética , Sulfonamidas/farmacocinética , Tiofenos/farmacocinética , Administração Tópica , Idoso , Inibidores da Anidrase Carbônica/sangue , Inibidores da Anidrase Carbônica/urina , Eritrócitos/metabolismo , Feminino , Glaucoma de Ângulo Aberto/sangue , Glaucoma de Ângulo Aberto/urina , Humanos , Masculino , Pessoa de Meia-Idade , Hipertensão Ocular/sangue , Hipertensão Ocular/urina , Sulfonamidas/sangue , Sulfonamidas/urina , Tiofenos/sangue , Tiofenos/urinaRESUMO
OBJECTIVE: To determine the pharmacokinetics of acetazolamide administered IV and orally to horses. ANIMALS: 6 clinically normal adult horses. PROCEDURE: Horses received 2 doses of acetazolamide (4 mg/kg of body weight, IV; 8 mg/kg, PO), and blood samples were collected at regular intervals before and after administration. Samples were assayed for acetazolamide concentration by high-performance liquid chromatography, and concentration-time data were analyzed. RESULTS: After IV administration of acetazolamide, data analysis revealed a median mean residence time of 1.71 +/- 0.90 hours and median total body clearance of 263 +/- 38 ml/kg/h. Median steady-state volume of distribution was 433 +/- 218 ml/kg. After oral administration, mean peak plasma concentration was 1.90 +/- 1.09 microg/ml. Mean time to peak plasma concentration was 1.61 +/- 1.24 hours. Median oral bioavailability was 25 +/- 6%. CONCLUSIONS AND CLINICAL RELEVANCE: Oral pharmacokinetic disposition of acetazolamide in horses was characterized by rapid absorption, low bioavailability, and slower elimination than observed initially after IV administration. Pharmacokinetic data generated by this study should facilitate estimation of appropriate dosages for acetazolamide use in horses with hyperkalemic periodic paralysis.
Assuntos
Acetazolamida/farmacocinética , Inibidores da Anidrase Carbônica/farmacocinética , Cavalos/fisiologia , Acetazolamida/administração & dosagem , Acetazolamida/sangue , Administração Oral , Animais , Área Sob a Curva , Disponibilidade Biológica , Inibidores da Anidrase Carbônica/administração & dosagem , Inibidores da Anidrase Carbônica/sangue , Cromatografia Líquida de Alta Pressão/métodos , Cromatografia Líquida de Alta Pressão/veterinária , Estudos Cross-Over , Feminino , Meia-Vida , Injeções Intravenosas/veterinária , Análise dos Mínimos Quadrados , MasculinoRESUMO
The selective inhibition of cancer-associated human carbonic anhydrase (CA) enzymes, specifically CA IX and XII, has been validated as a mechanistically novel approach toward personalized cancer management. Herein we report the design and synthesis of a panel of 24 novel glycoconjugate primary sulfonamides that bind to the extracellular catalytic domain of CA IX and XII. These compounds were synthesized from variably acylated glycopyranosyl azides and either 3- or 4-ethynyl benzene sulfonamide using Cu(I)-catalyzed azide alkyne cycloaddition (CuAAC). The CA enzyme inhibition profile for all compounds was determined, while in vitro metabolic stability, plasma stability, and plasma protein binding for a representative set of compounds was measured. Our findings demonstrate the influence of the differing acyl groups on these key biopharmaceutical properties, confirming that acyl group protected carbohydrate-based sulfonamides have potential as prodrugs for selectively targeting the extracellular cancer-associated CA enzymes.
Assuntos
Antígenos de Neoplasias/efeitos dos fármacos , Inibidores da Anidrase Carbônica/síntese química , Anidrases Carbônicas/efeitos dos fármacos , Pró-Fármacos/síntese química , Sulfonamidas/síntese química , Antígenos de Neoplasias/metabolismo , Células CACO-2 , Anidrase Carbônica IX , Inibidores da Anidrase Carbônica/sangue , Inibidores da Anidrase Carbônica/química , Anidrases Carbônicas/metabolismo , Domínio Catalítico/efeitos dos fármacos , Permeabilidade da Membrana Celular , Estabilidade Enzimática , Glicoconjugados/síntese química , Humanos , Neoplasias/enzimologia , Pró-Fármacos/química , Relação Estrutura-AtividadeAssuntos
Anticonvulsivantes/farmacologia , Inibidores da Anidrase Carbônica/farmacologia , Epilepsia/tratamento farmacológico , Sulfonamidas/farmacologia , Adulto , Compostos de Anilina/sangue , Compostos de Anilina/farmacologia , Anticonvulsivantes/sangue , Inibidores da Anidrase Carbônica/sangue , Ensaios Clínicos como Assunto , Eletroencefalografia , Eritrócitos/análise , Feminino , Meia-Vida , Humanos , Raios Infravermelhos , Cinética , Masculino , Pessoa de Meia-Idade , Análise Espectral , Sulfonamidas/sangue , Sulfonas/sangue , Sulfonas/farmacologiaAssuntos
Acetazolamida/sangue , Acetazolamida/administração & dosagem , Inibidores da Anidrase Carbônica/sangue , Cromatografia Líquida de Alta Pressão/métodos , Cromatografia Líquida de Alta Pressão/estatística & dados numéricos , Determinação de Ponto Final , Humanos , Reprodutibilidade dos Testes , Espectrofotometria Ultravioleta/métodos , Espectrofotometria Ultravioleta/estatística & dados numéricosAssuntos
Inibidores da Anidrase Carbônica/uso terapêutico , Glaucoma de Ângulo Aberto/tratamento farmacológico , Sulfonamidas/uso terapêutico , Tiazinas/uso terapêutico , Inibidores da Anidrase Carbônica/sangue , Inibidores da Anidrase Carbônica/farmacologia , Ensaios Clínicos como Assunto , Humanos , Pressão Intraocular/efeitos dos fármacos , Sulfonamidas/sangue , Sulfonamidas/farmacologia , Tiazinas/sangue , Tiazinas/farmacologiaRESUMO
Using a pH stat method, we measured the activity of carbonic anhydrase (CA) from dog erythrocytes in the presence of various amounts of dog plasma. A plasma factor appeared to be able to inhibit about 86% of the total CA activity, corresponding to the relative activity of CA II. Naiodoacetate was shown to inhibit the total CA activity up to about 13%, corresponding to the relative activity of CA I. C1- inhibited the total CA activity up to about 20%, presumably mainly through its strong influence on Ca I. It is concluded that with a degree of haemolysis of up to 3%, no appreciable plasma CA activity will occur.